Technologies

AbTherx's Atlas™ Mice include a clinically validated bispecific antibody format most similar to a native antibody configuration and a long CDR3 antibody technology using native human sequences that will improve the chance of success against challenging targets such as GPCRs and ion channels. AbTherx has also established more approachable partnering models for their transgenic mice expressing full human antibody diversity.

Binary Light Chain

Binary Fixed Light Chain Mouse

Binary Fixed Light Chain Mouse

  • Enables a clinically-validated bispecific antibody format most similar to a native antibody configuration
  • Novel binary feature allows for target-driven expression from one of two fixed light chain cassettes
  • Increases hit recovery, as the two light chain choices have overlapping but distinct abilities to pair with cognate heavy chains
Long CDR3

Long CDR3 Mouse

Long CDR3 Mouse

  • Addresses an unmet medical need, with few approaches or technologies able to effectively access these recalcitrant target classes (e.g., GPCRs and ion channels) with therapeutic mAbs
  • Makes use of natural mechanisms for long CDR3 generation, typically a rare event, but constrains the system to only use long CDR3s
  • All introduced sequences are of human origin, improving upon platforms from other species (e.g., ruminant-based) that may suffer from immunogenicity or expression issues
Full Human Diversity

Full Human Diversity Mouse

Full Human Diversity Mouse

  • Full-diversity human heavy chain + κ-light chain
  • Transgenes used are comprised of compact arrays that eliminate all the pseudogenes normally found in the Ig locus (for both HC and κ-LC), leading to more productive B-cell rearrangements
  • Specific variable sequences used avoid patented or FTO-excluded variants
  • Variable regions used comprise >99% of known or expressed human sequences